I den totale AKS- population viste en analyse af hvert af de sekundære endepunkter en signifikant fordel (p < 0. 001) ved prasugrel sammenlignet med clopidogrel.
In the All ACS population, analysis of each of the secondary endpoints showed a significant benefit (p < 0.001) for prasugrel versus clopidogrel.